Literature DB >> 23251737

Therapeutic benefits of budesonide in gastroenterology.

Sarah O'Donnell1, Colm A O'Morain.   

Abstract

Budesonide is a synthetic steroid of the glucocorticoid family with a high topical anti-inflammatory activity. Enteric-coated formulations resist gastric-acid degradation, delivering active drug to the small intestine and proximal colon. Budesonide has a high first-pass metabolism with minimal systemic absorption. It is therefore felt to cause fewer side effects than traditional glucocorticosteroids and to be generally well tolerated. The aim of this paper is to examine the utility of this medication in frequently encountered gastrointestinal conditions: Crohn's disease, ulcerative colitis, microscopic colitis and eosinophilic oesophagitis. A Medline search was performed to find published original research and review articles relating to the use budesonide in common gastroenterological conditions. The results showed that budesonide is efficacious in the induction and short-term maintenance of Crohn's disease. Budesonide is the best-documented treatment for microscopic colitis. It is well proven to be effective in the induction of remission in collagenous colitis but its use in lymphocytic colitis remains less well documented. In conclusion, budesonide is an effective glucocorticosteroid therapy for many chronic gastrointestinal diseases. In combination with its efficacy, the low incidence of serious side effects associated with this drug should keep it at the forefront in the therapeutic arsenal of any gastroenterologist.

Entities:  

Keywords:  Crohn's disease; budesonide; eosinophilic oesophagitis; microscopic colitis; pouchitis; ulcerative colitis

Year:  2010        PMID: 23251737      PMCID: PMC3513866          DOI: 10.1177/2040622310379293

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  59 in total

1.  Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.

Authors:  R Löfberg; A Danielsson; O Suhr; A Nilsson; R Schiöler; A Nyberg; R Hultcrantz; B Kollberg; R Gillberg; R Willén; T Persson; L Salde
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

2.  Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.

Authors:  M Campieri; A Ferguson; W Doe; T Persson; L G Nilsson
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

3.  Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. The Danish Budesonide Study Group.

Authors: 
Journal:  Scand J Gastroenterol       Date:  1991-12       Impact factor: 2.423

4.  Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects.

Authors:  S Edsbäcker; P Andersson; C Lindberg; J Paulson; A Ryrfeldt; A Thalén
Journal:  Drug Metab Dispos       Date:  1987 May-Jun       Impact factor: 3.922

5.  Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis.

Authors:  M Lémann; A Galian; P Rutgeerts; R Van Heuverzwijn; A Cortot; J M Viteau; A Elewaut; J Belaiche; E Froguel; R Modigliani
Journal:  Aliment Pharmacol Ther       Date:  1995-10       Impact factor: 8.171

6.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

7.  A comparison of budesonide with prednisolone for active Crohn's disease.

Authors:  P Rutgeerts; R Löfberg; H Malchow; C Lamers; G Olaison; D Jewell; A Danielsson; H Goebell; O O Thomsen; H Lorenz-Meyer
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

8.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

Authors:  G R Greenberg; B G Feagan; F Martin; L R Sutherland; A B Thomson; C N Williams; L G Nilsson; T Persson
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

9.  Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.

Authors:  R Keller; R Stoll; E C Foerster; N Gutsche; W Domschke
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

10.  Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.

Authors:  G D'Haens; A Verstraete; K Cheyns; I Aerden; R Bouillon; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  1998-05       Impact factor: 8.171

View more
  13 in total

1.  Chronic Diarrhea Related to Colonic Malakoplakia Successfully Treated with Budesonide in a Kidney Transplant Recipient.

Authors:  Hayretdin Koklu; Eylem Imamoglu; Nomingerel Tseveldorj; Cenk Sokmensuer; Taylan Kav
Journal:  Am J Gastroenterol       Date:  2018-10-24       Impact factor: 10.864

2.  Evidence of Systemic Absorption of Enteral Budesonide in Patients with Fontan-Associated Protein-Losing Enteropathy.

Authors:  Richard Ogden Roberts; Michael V Di Maria; Dania Brigham; Stephanie Hsu
Journal:  Pediatr Cardiol       Date:  2019-11-09       Impact factor: 1.655

3.  Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

Authors:  Abhijit A Date; Gilad Halpert; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Peter Dimitrion; Janani Narayan; Hannah Zierden; Kalpana Betageri; Olivia Musmanno; Helen Wiegand; Xinglu Huang; Sanjeev Gumber; Justin Hanes; Laura M Ensign
Journal:  Biomaterials       Date:  2018-09-07       Impact factor: 12.479

4.  FK506-Binding Protein 5 mRNA Levels in Ileal Mucosa Are Associated with Pouchitis in Patients with Ulcerative Colitis.

Authors:  Toshimitsu Araki; Mikio Kawamura; Koji Tanaka; Yoshiki Okita; Hiroyuki Fujikawa; Keiichi Uchida; Yuji Toiyama; Yasuhiro Inoue; Yasuhiko Mohri; Masato Kusunoki
Journal:  Dig Dis Sci       Date:  2015-01-18       Impact factor: 3.199

Review 5.  Pancreas and Adverse Drug Reactions: A Literature Review.

Authors:  Konrad Sosnowski; Piotr Nehring; Adam Przybyłkowski
Journal:  Drug Saf       Date:  2022-07-05       Impact factor: 5.228

Review 6.  p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes.

Authors:  Ramkumar Menon; John Papaconstantinou
Journal:  Expert Opin Ther Targets       Date:  2016-08-04       Impact factor: 6.902

7.  Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity.

Authors:  Niels Teich; Wolfgang Mohl; Bernd Bokemeyer; Burkhard Bündgens; Jürgen Büning; Stephan Miehlke; Dietrich Hüppe; Christian Maaser; Tobias Klugmann; Wolfgang Kruis; Britta Siegmund; Ulf Helwig; Joseph Weismüller; Attyla Drabik; Andreas Stallmach
Journal:  J Crohns Colitis       Date:  2015-10-13       Impact factor: 9.071

Review 8.  MMX® technology and its applications in gastrointestinal diseases.

Authors:  Silvia Nardelli; Laura Francesca Pisani; Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli
Journal:  Therap Adv Gastroenterol       Date:  2017-05-25       Impact factor: 4.409

9.  Effect of Poly(vinyl alcohol) on Nanoencapsulation of Budesonide in Chitosan Nanoparticles via Ionic Gelation and Its Improved Bioavailability.

Authors:  Georgia Michailidou; Nina Maria Ainali; Eleftheria Xanthopoulou; Stavroula Nanaki; Margaritis Kostoglou; Emmanuel N Koukaras; Dimitrios N Bikiaris
Journal:  Polymers (Basel)       Date:  2020-05-12       Impact factor: 4.329

Review 10.  Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis.

Authors:  Marisa Iborra; Diego Alvarez-Sotomayor; Pilar Nos
Journal:  Clin Exp Gastroenterol       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.